A double-blind study to characterize the effect of ampreloxetine on cardiac repolarization in healthy subjects.

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled, Thorough QT Study to Evaluate the Effect of Ampreloxetine on Cardiac Repolarization in Healthy Subjects

An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal hepatic function.

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

A Phase 1, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics of Ampreloxetine Following a Single-dose in Subjects With Mild, Moderate, and Severe Hepatic Impairment and in Matching Healthy Subjects

Treatment Trials

Focus your search

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Description

Conditions

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Description

Conditions